Karyopharm Therapeutics Stock News

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Investment analysts at Wedbush upped their FY2021 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a note issued to investors on Tuesday, December 21st. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.81) per share for the year, up from their prior estimate of []

Karyopharm Therapeutics Inc (NASDAQ: KPTI ) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm''s Nexpovio (selinexor) in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America Full story available on Benzinga.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at $6.47 at last check on Tuesday, December 21, made an upward move of 1.65% on its previous day’s price. Looking at the stock we see that its previous close was $6.36 and the beta (5Y monthly) reads 0.20 with the day’s price range being $5.88 – $6.48. In terms … Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? Read More »

Karyopharm Therapeutics Inc (NASDAQ: KPTI) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm's Nexpovio (selinexor) in Europe and other

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has a beta value of -0.03 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $468.80M, closed the last trade at $6.36 per share which meant it gained $0.21 on the day or 3.41% during that session. The KPTI stock price is -183.02% … Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win Read More »

Brokerages expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to announce sales of $29.61 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Karyopharm Therapeutics earnings, with the lowest sales estimate coming in at $24.30 million and the highest estimate coming in at $38.69 million. Karyopharm Therapeutics posted sales of $35.10 million []

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares, rose in value on Thursday, 12/16/21, with the stock price down by -4.00% to the previous days close as strong demand from buyers drove the stock to $6.00. Actively observing the price movement in the last trading, the stock closed the session at $6.25, falling within a range of $5.825 Karyopharm Therapeutics Inc. (NASDAQ: KPTI): Moving Toward A Higher Share Price Read More »

In the last trading session, 2.35 million shares of the Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were traded, and its beta was -0.02. Most recently the companys share price was $5.99, and it changed around -$0.47 or -7.28% from the last close, which brings the market valuation of the company to $490.28M. KPTI currently trades at a Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Shares Could Drop Up To -334.06% Read More »

-- 40% of Patients with Myelofibrosis Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Response, Defined as 35% Spleen Volume Reduction --

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target raised by Royal Bank of Canada from $8.00 to $9.00 in a report issued on Thursday, Price Targets.com reports. They currently have a sector perform rating on the stock. Several other analysts have also recently commented on KPTI. Zacks Investment Research upgraded Karyopharm Therapeutics from a sell rating […]

Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature recently appointed Teddy C. Scott, Ph.D., J.D to serve on the board of dire

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Wall Street brokerages predict that Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will post earnings per share of ($0.72) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Karyopharm Therapeutics earnings. The highest EPS estimate is ($0.58) and the lowest is ($0.92). Karyopharm Therapeutics reported earnings of ($0.59) per share in []